Navigation Menu

Poll

How do you rate your relationship with your CFO

Very good, they understand TP requirements well enough
8%
Good but there's room for improvement
30%
Good but TP is not their main concern
52%
They do not understand the requirements of the TP department
10%


View previous poll results

Skip to Navigation menu Skip to top of page

Ballentine Barbera recruits three new faces

February 18, 2010

The Ballentine Barbera Group, a Charles River Associates company that specialises in transfer pricing, has added three new consultants

Brad Rolph, who used to be a partner and chief economist of the national transfer pricing group at Deloitte & Touche in Canada joins the firm as a vice president in Toronto. He has advised multinational companies on the preparation and defence of a variety of intercompany transactions in different industries. He has also worked on planning, implementation, taxpayer-initiated adjustments, voluntary disclosure, litigation, competent authority, and advance pricing arrangement (APA) assignments.

Paul Wilmshurst becomes leader of the UK transfer pricing practice in London. His experience includes designing practical documentation solutions to helping major companies defend contentious transfer pricing arrangements. His tax efficient supply chain work has included identifying and valuing different types of intangibles, assessing and modelling economic risks, and designing commercial transfer pricing policies. He was previously a transfer pricing economist at KPMG and at Deloitte.

Guy Kersch has become a senior consultant, Europe. His transfer pricing expertise includes work on (de)mergers and acquisitions, planning, and tax audit in various industries, including chemicals, turn-key plants, construction, engineering, and pharmaceuticals. He will continue his practice at his own firm, GK International Tax Consulting. He was formerly senior transfer pricing counsel for Grant Thornton and before that, worked in Europe for US global pharmaceutical companies such as Monsanto, Pharmacia and Pfizer.